Carlo Garufi

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial

Françis Lévi, Rachid Zidani, Jean-Michel Vannetzel et al. · JNCI Journal of the National Cancer Institute · 1994 · 389 citations

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi et al. · Modern Pathology · 2015 · 309 citations · Full text

Her2 Scoring System, Colorectal Surgery, Medicine +7

Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer

Pasquale F. Innominato, C. Focan, Thierry Gorlia et al. · Cancer Research · 2009 · 245 citations · Full text

Biological Correlate, Quality Of Life, Cancer Management +21

Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

Sylvie Giacchetti, Georg A. Bjarnason, Carlo Garufi et al. · Journal of Clinical Oncology · 2006 · 220 citations · Full text